Progress Study
IBSA Group and Inception Fertility want to make the embryo transfer process a little simpler for patients—and we need your help to make that progress.
IBSA, a multinational pharmaceutical company, recognizes current methods of administering progesterone before and after a frozen embryo transfer (FET) can be painful, messy, and stressful for patients. The company has partnered with Inception Fertility and its family of brands, including the Prelude Network™, to complete a research study evaluating the effectiveness of administering progesterone by subcutaneous injection, an injection under the skin, rather than painful daily injections into a muscle or messy vaginal creams/gels or inserts.
A hormone that plays an important role in early pregnancy, progesterone is considered the standard of care for support during the luteal phase of a woman’s menstrual cycle, when the lining of the uterus thickens to support a potential pregnancy. During a FET cycle, progesterone is usually administered for 4 days prior to the transfer. If the cycle results in a pregnancy, expectant mothers will continue to administer progesterone up to the 10-12th week of pregnancy. This study seeks to find an easier way to administer this vital hormone, helping to make the embryo transfer process more patient-friendly and less painful.
IBSA, a multinational pharmaceutical company, recognizes current methods of administering progesterone before and after a frozen embryo transfer (FET) can be painful, messy, and stressful for patients. The company has partnered with Inception Fertility and its family of brands, including the Prelude Network™, to complete a research study evaluating the effectiveness of administering progesterone by subcutaneous injection, an injection under the skin, rather than painful daily injections into a muscle or messy vaginal creams/gels or inserts.
A hormone that plays an important role in early pregnancy, progesterone is considered the standard of care for support during the luteal phase of a woman’s menstrual cycle, when the lining of the uterus thickens to support a potential pregnancy. During a FET cycle, progesterone is usually administered for 4 days prior to the transfer. If the cycle results in a pregnancy, expectant mothers will continue to administer progesterone up to the 10-12th week of pregnancy. This study seeks to find an easier way to administer this vital hormone, helping to make the embryo transfer process more patient-friendly and less painful.
Key Participant Requirements
The Progress Study is open to women ages 35-42 who have regular menstrual cycles (24-38 days) and are planning a single embryo transfer. Participants must:
- Have completed a normal uterine cavity evaluation within the past year (hysteroscopy, hysterosalpingogram, or SIS)
- Have a normal pap smear
- Must not have a medical history of severe endometriosis, recurrent pregnancy loss, diabetes mellitus, uncontrolled thyroid dysfunction, hepatic or renal impairment, autoimmune disease
For a complete list of eligibility criteria, visit ClinicalTrials.gov: NCT04549116
Key Participant Requirements
The Progress Study is open to women ages 35-42 who have regular menstrual cycles (24-38 days) and are planning a single embryo transfer. Participants must:
- Have completed a normal uterine cavity evaluation within the past year (hysteroscopy, hysterosalpingogram, or SIS)
- Have a normal pap smear
- Must not have a medical history of severe endometriosis, recurrent pregnancy loss, diabetes mellitus, uncontrolled thyroid dysfunction, hepatic or renal impairment, autoimmune disease
For a complete list of eligibility criteria, visit ClinicalTrials.gov: NCT04549116
Attend scheduled clinic visits.
Receive study medications to self-administer as instructed by the clinic staff.
Attend scheduled clinic visits.
Have blood drawn to evaluate hormone levels.
Complete transvaginal ultrasounds designed to monitor changes to the ovaries, uterine lining, or pregnancy, if applicable.
Receive study medications to self-administer as instructed by the clinic staff.
As part of the study, participants will receive
a credit toward their IVF/FET cycle cost, PGT-A testing via Igenomix, progesterone and Ovidrel, a medication that induces ovulation.
Sign up
©2023 Inception Fertility, Inc. All rights reserved.